Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?
Recursion Pharmaceuticals (NASDAQ: RXRX) is not the most famous artificial intelligence (AI) stock on the market, but the biotech (or techbio) company has attracted the attention of some big names. Recursion has partnered with the AI juggernaut Nvidia to build a powerful supercomputer, for example.It is also attracting interest from some prominent Wall Street figures, including Cathie Wood, the CEO of Ark Invest. The investment firm owns about $164 million worth of the stock, as of this writing. Yet, Recursion has not been performing well -- shares are down by 19% this year.Should investors take this opportunity to buy the stock on the dip?Continue reading
Recursion Pharmaceuticals (NASDAQ: RXRX) is not the most famous artificial intelligence (AI) stock on the market, but the biotech (or techbio) company has attracted the attention of some big names. Recursion has partnered with the AI juggernaut Nvidia to build a powerful supercomputer, for example.
It is also attracting interest from some prominent Wall Street figures, including Cathie Wood, the CEO of Ark Invest. The investment firm owns about $164 million worth of the stock, as of this writing. Yet, Recursion has not been performing well -- shares are down by 19% this year.
Should investors take this opportunity to buy the stock on the dip?
